Immutep Quarterly Activities Report Q4 FY23
Media Release Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational...
Media Release Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational...
PALO ALTO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180LS” or the “Company”), today...
Media Release Mini Oral presentation will include data from TACTI-002 Phase II trial evaluating chemotherapy-free IO combination of efti plus...
Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.Tafenoquine is the...
Highlights: ATH434-201 Phase 2 study on track to complete enrollment in Q3 2023 with top-line data expected by the end...
Cash balance of $18.5 million as at March 31, 2023Revenue of $3.95 million (vs 2022: $2.3 million, an increase of...
New Product Showing Encouraging Early ResultsSHERMAN OAKS, CA / ACCESSWIRE / July 31, 2023 / Avenir Wellness Solutions, Inc. (OTC:CURR)...
LUND, SE / ACCESSWIRE / July 31, 2023 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Tumorad® into clinicJANUARY - JUNE IN BRIEFNet...